Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-09-23
2008-09-23
Allen, Marianne P (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000
Reexamination Certificate
active
10375765
ABSTRACT:
Pharmaceutical compositions that comprise a pharmaceutically acceptable carrier and either a therapeutically effective amount of an ECM-binding fragment of Ang-1 protein that comprises SEQ ID NO:1 and/or SEQ ID NO:2 or a homologous peptide thereof and pharmaceutical compositions that comprise a pharmaceutically acceptable carrier and a vector comprising a nucleic acid molecule that comprises the nucleotide sequence that encodes an ECM-binding fragment of Ang-1 protein that comprises SEQ ID NO:1 and/or SEQ ID NO:2 or a homologous peptide thereof are disclosed. Methods of using such compositions to treat individuals suspected of having coronary artery disease, vascular disease or a condition involving ischemia and to promote angiogenesis, endothelial survival and maintaining vascular integrity are disclosed. Methods to identify compounds that modulates binding of Ang-1 to ECM are disclosed. Pharmaceutical compositions which comprise a therapeutically effective amount of Ang-2 protein and/or a vector comprising a nucleic acid molecule that comprises the nucleotide coding sequence of Ang-2 and methods of using such compositions to treat individuals suspected of having cancer are disclosed.
REFERENCES:
patent: 6916637 (2005-07-01), Rieping et al.
patent: WO 96/31598 (1996-10-01), None
Hattori et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. 193:1005-1014, 2001.
Rudinger, J. Characteristics of the amino acids as components of a peptide hormone sequence. In: Peptide hormones (Parsons, JA, ed.), University Park Press, Baltimore, pp. 1-7, 1976.
Ngo et al. Computational complexity, protein structure prediction and the Levinthal Paradox. In: The protein folding problem and tertiary structure prediction (Merz et al., eds.), Birkhauser, Boston, pp. 1-491-495, 1994.
Koblizek et al., Current Biology, 8:529-432, 1998.
Asahara, Takayuki, et al. “Tie2 Receptor Ligands, Angiopoietin-1 and Angiopoietin-2, Modulate VEGF-induced Postnatal Neovascularization” Circulation Res. (1998) 83:233-240.
Davis, Samuel, et al. “Isolation of Angiopoietin-1, A Ligand for the Tie2 Receptor, by Secretion-Trap Expression Cloning”, Cell (1996) 87:1161-1169.
Dumont, Daniel J., et al. “Dominant-Negative and Targeted Null Mutations in the Endothelial Receptor Tyrosine Kinase, TEK, Reveal a Critical Role in Vasculogenesis of the Embryo” Genes & Development (1994) 8:1897-1909.
Fidler, Isaiah J., et al. “The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis” Cell. (1994) 79:185-188.
Fong, Guo-Hua., et al. “Role of the FLT-1 Receptor Tyrosine Kinase in Regulating the Assembly of Vascular Endothelium” Nature (1995) 376:66-70.
Gale, Nicolas W., “Growth Factors Acting via Endothelial Cell-Specific Receptor Tyrosine Kinases: VEGF's Angiopoietins, and Ephrins in Vascular Development” Genes&Development (1999) 13:1055-1066.
Hanahan, Douglas, et al. “Patterns and Emerging Mechanisms of the Angiogenic Switch During Tumorigenesis” Cell (1996) 86:353-364.
Hanahan, Douglas, et al, “Signaling Vascular Morphogenesis and Maintenance” Science (1997) 277:48-50.
Hayes, Andrew J., et al. “Angiopoietin-1 and its Receptor Tie-2 Participate in the Regulation of Capillary-Like Tubule Formation and Survival of Endothelial Cells” Microvascular Research. (1999) 58:244-237.
Holash, J., et al. “New Model of Tumor Angiogenesis: Dymanic Balance Between Vessel Regression and Growth Mediated by Angiopoietins and VEGF” Oncogene. (1999) 18: 5356-5362.
Holash, J., et al. “Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF” Science. (1999) 284:1994-1998.
Holmgren, Lars, et al. “Dormancy of Micrometastases: Balanced Proliferation and Apoptosis in the Presence of Angiogenesis Suppression” Nature Medicine. (1995) 2: 149-153.
Ingber, Donald E., et al. “How Does Extracellular Matrix Control Capillary Morphogenesis?” Cell (1989) 58:803-805.
Kim, Injune, et al. “Angiopoietin-1 Regulates Endothelial Cell Survival Through the Phosphatidylinositol 3'-KINASE/AKT Signal Transduction Pathway” Circ Res. (2000) 86:24-29.
Kim, Injune, et al. “Tumor Necrosis Factor-α Upregulates Angiopoietin-2 in Human Umbilical Vein Endothelial Cells” Biochemical and Biophysical Research Communications. (2000) 269:361-365.
Kim, Jin K., et al. “Inhibtion of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth In Vivo” Nature (1993) 362:841-844.
Klagsbrun, Michael “Mediators of Angiogenesis: The Biological Significance of Basic Fibroblast Growth Factor (bFGF)-Heparin and Heparan Sulfate Interactions” Cancer Biology. (1992) 3:81-87.
Koblizek Thomas I., et al. “Angiopoietin-1 Induces Sprouting Angiogenesis In Vitro” Current Biology (1998) 8:529-532.
Kuno, Kouji, et al. “Adamts-1 Protein Anchors at the Extracellular Matrix Through the Thrombospondin Type I Motifs and its Spacing Region” The Journal of Biological Chemistry. (1998) 273:13912-13917.
Kwak, Hee Jin, et al. “Angiopoietin-1 Inhibits Irradiation- and Mannitol-Tnduced Apoptosis in Endothelial Cells” Circulation (2000) 101:2317-2324.
Lauren, Juha, et al. Is Angiopoietin-2 Necessary for the Initiation of Tumor Angiogenesis? American Journal of Pathology. (1998) 153:1333-1339.
Maisonpierre, Peter C., et al. “Angiopoietin-2, A Natural Antagonists for Tie2 That Disrupts in Vivo Angiogenesis” Science (1997) 277:55-60.
Mandriota, Stefano, et al. “Regulation of Angiopoietin-2 mRNA Levels in Bovine Microvascular Endothelial Cells by Cytokines and Hypoxia” Circulation Res. (1998) 83: 852-859.
Massague, Joan “The Transforming Growth Factor-β Family” Annu. Rev. Cell Biol. (1990) 6:597-641.
Millauer, Birgit, et al. “Glioblastoma Growth Inhibited in Vivo by a Dominant-Negative FLK-1 Mutant” Nature (1994) 367:576-579.
Mustonen Tuija, et al. “Endothelial Receptor Tyrosine Kinases Involved in Angiogenesis” The Journal of Cell Biology (1995) 129:895-898.
O'Reilly Michael S., et al. “Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma” Cell. (1994) 79:315-328.
Oh, Hideyasu, et al. “Hypoxia and Vascular Endothelial Growth Factor Selectively Up-Regulate Angiopoietin-2 in Bovine Microvascular Endothelial Cells” The Journal of Biological Chemistry. (1999) 274:15732-15739.
Ortega, Nathalie, et al. “Control of Vascular Endothelial Growth Factor Angiogenic Activity by the Extracellular Matrix” Biology of the Cell. (1998) 90:381-390.
Papapetropoulos, Andreas, et al. “Angiopoietin-1 Inhibits Endothelial Cell Apoptosis via the Akt/Survivin Pathway” The journal of Biological Chemistry. (2000) 275:9102-9105.
Procopio, William N., et al. “Angiopoietin-1 and -2 Coiled Coil Domains Mediate Distinct Homo-Oligomerization Patterns, but Fibrinogen-Like Domains Mediate Ligand Activity” The Journal of Biological Chemistry (1999) 274:30196-30201.
Risau, Werner, et al. “Mechanisms of Angiogenesis” Nature (1997) 386:671-674.
Sato, Thomas N., et al. “Distinct Roles of the Receptor Tyrosine Kinases Tie-1 and Tie-2 in Blood Vessel Formation” Nature (1995) 376:70-74.
Sherwood, Louis M., et al. “Tumor Angiogenesis: Therapeutic Implications” The New England Journal of Medicine (1971) 285:1182-1186.
Stratmann, Astrid, et al. “Cell Type-Specific Expression of Angiopoietin-1 and Angiopoietin-2 Suggests a Role in Glioblastoma Angiogenesis” (1998) 153:1459-1466.
Suri, Chitra, et al. “Increased Vascularization in Mice Overexpressing Angiopoietin-1” Science (1998) 282:468-471.
Suri, Chitra, et al. “Requisite Role of
Allen Marianne P
Pepper Hamilton LLP
The Trustees of the University of Pennsylvania
LandOfFree
Methods and pharmaceuticals compositions for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and pharmaceuticals compositions for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and pharmaceuticals compositions for treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3920085